Intragastric acid control in non-steroidal anti-inflammatory drug users: Comparison of esomeprazole, lansoprazole and pantoprazole

Alimentary Pharmacology and Therapeutics

Volumn 23, Issue 8, 2006, Pages 1189-1196

  Goldstein, J L ^a   Miner Jr , P B ^b   Schlesinger, P K ^a   Liu, S ^c   Silberg, D G ^c  

^a UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^b UNIVERSITY OF OKLAHOMA HEALTH SCIENCES CENTER   (United States)

^c ASTRAZENECA   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTACID AGENT; ATTAPULGITE; CELECOXIB; CYCLOOXYGENASE 2 INHIBITOR; ESOMEPRAZOLE; ETODOLAC; IBUPROFEN; LANSOPRAZOLE; MELOXICAM; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; PANTOPRAZOLE; ROFECOXIB; VALDECOXIB;

ABDOMINAL DISTENSION; ABDOMINAL PAIN; ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIARRHEA; DRUG EFFICACY; DRUG SELECTIVITY; DYSPEPSIA; FEMALE; HEADACHE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NAUSEA; PH MEASUREMENT; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; STOMACH PH; STOMACH ULCER; TREATMENT OUTCOME;

2-PYRIDINYLMETHYLSULFINYLBENZIMIDAZOLES; ADOLESCENT; ADULT; AGED; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTI-ULCER AGENTS; BENZIMIDAZOLES; CROSS-OVER STUDIES; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; FEMALE; GASTRIC ACID; GASTRIC ACIDITY DETERMINATION; HUMANS; HYDROGEN-ION CONCENTRATION; LEAST-SQUARES ANALYSIS; MALE; MIDDLE AGED; OMEPRAZOLE; PROTON PUMPS; SULFOXIDES;

EID: 33646889328     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/j.1365-2036.2006.02867.x     Document Type: Article

References (25)

1. Laine L. The role of proton pump inhibitors in NSAID-associated gastropathy and upper gastrointestinal symptoms. Rev Gastroenterol Disord 2003 3 Suppl. 4 S30 9.
2. Hernandez-Diaz S Rodriguez LAG. Association between nonsteroidal anti-inflammatory drugs and upper gastrointestinal tract bleeding/perforation: an overview of epidemiologic studies published in the 1990s. Arch Intern Med 2000 160 : 2093 9.
3. Savarino V Mela GS Zentilin P, et al. Effect of one-month treatment with nonsteroidal antiinflammatory drugs (NSAIDs) on gastric pH of rheumatoid arthritis patients. Dig Dis Sci 1998 43 : 459 63.
4. Ligumsky M Goto Y Yamada T. Prostaglandins mediate inhibition of gastric acid secretion by somatostatin in the rat. Science 1983 219 : 301 3.
5. Elliott SL Ferris RJ Giraud AS, et al. Indomethacin damage to rat gastric mucosa is markedly dependent on luminal pH. Clin Exp Pharmacol Physiol 1996 23 : 432 4.
6. Agrawal NM Campbell DR Safdi MA Lukasik NL Huang B Haber MM. Superiority of lansoprazole vs. ranitidine in healing nonsteroidal anti-inflammatory drug-associated gastric ulcers: results of a double-blind, randomized, multicenter study. NSAID-Associated Gastric Ulcer Study Group. Arch Intern Med 2000 160 : 1455 61.
7. Ekstrom P Carling L Wetterhus S, et al. Prevention of peptic and dyspeptic ulcer symptoms with omeprazole in patients receiving continuous non-steroidal anti-inflammatory drug therapy. A Nordic multicentre study. Scand J Gastroenterol 1996 31 : 753 8.
8. Yeomans ND Tulassay Z Juhasz L, et al. A comparison of omeprazole with ranitidine for ulcers associated with nonsteroidal anti-inflammatory drugs. Acid-Suppression Trial: Ranitidine versus Omeprazole for NSAID-Associated Ulcer Treatment (ASTRONAUT) Study Group. N Engl J Med 1998 338 : 719 26.
9. Hawkey CJ Karrasch JA Szczepañski L, et al. Omeprazole compared with misoprostol for ulcers associated with nonsteroidal anti-inflammatory drugs. Omeprazole versus Misoprostol for NSAID-Induced Ulcer Management (OMNIUM) Study Group. N Engl J Med 1998 338 : 727 34.
10. Lai KC Lam SK Chu KM, et al. Lansoprazole reduces ulcer relapse after eradication of Helicobacter pylori in non-steroidal anti-inflammatory drug users - a randomised trial. Aliment Pharmacol Ther 2003 18 : 829 36.
11. Goldstein JL Johanson J Suchower L Brown K. Esomeprazole vs ranitidine for the healing of NSAID-induced ulcers. Am J Gastroenterol 2005 100 : 2650 7.
12. Stupnicki T Dietrich K Gonzalez-Carro P, et al. Efficacy and tolerability of pantoprazole compared with misoprostol for the prevention of NSAID-related gastrointestinal lesions and symptoms in rheumatic patients. Digestion 2003 68 : 198 208.
13. Hawkey C Talley NJ Yeomans ND, et al. Improvements with esomeprazole in patients with upper gastrointestinal symptoms taking non-steroidal anti-inflammatory drugs, including selective COX-2 inhibitors. Am J Gastroenterol 2005 100 : 1028 36.
14. American College of Rheumatology Subcommittee on Osteoarthritis Guidelines. Recommendations for the medical management of osteoarthritis of the hip and knee. Arthritis Rheum 2000 43 : 1905 15.
15. American College of Rheumatology Subcommittee on Rheumatoid Arthritis Guidelines. Guidelines for the management of rheumatoid arthritis. Arthritis Rheum 2002 46 : 328 46.
16. Kimmey MB Lanas A. Review article: appropriate use of proton pump inhibitors with traditional nonsteroidal anti-inflammatory drugs and COX-2 selective inhibitors. Aliment Pharmacol Ther 2004 19 Suppl. 1 60 5.
17. Gardner JD Rodriguez-Stanley S Robinson M. Integrated acidity and the pathophysiology of gastroesophageal reflux disease. Am J Gastroenterol 2001 96 : 1363 70.
18. Hoogerwerf WA Pasricha PJ. Agents used for control of gastric acidity and treatment of peptic ulcers and gastroesophageal reflux disease. In : Hardman JG Limbird LE Gilman AG, eds. Goodman & Gilman's the Pharmacological Basis of Therapeutics, 10th edn. New York : McGraw-Hill, 2001 : 1005 20.
19. Miner P Katz PO Chen Y Sostek M. Gastric acid control with esomeprazole, lansoprazole, omeprazole, pantoprazole, and rabeprazole: a five-way crossover study. Am J Gastroenterology 2003 98 : 2616 20.
20. Taha AS Hudson N Hawkey CJ, et al. Famotidine for the prevention of gastric and duodenal ulcers caused by nonsteroidal antiinflammatory drugs. N Engl J Med 1996 334 : 1435 9.
21. Scheiman JM Yeomans N Talley N, et al. Prevention of ulcers by esomeprazole in at-risk patients using non-selective NSAIDs and COX-2 inhibitors. Am J Gastroenterol 2006. Available online at http://www.blackwell- synergy.com/loi/ajg ; publication date 22 February 2006; doi: 10.1111/j.1572-0241.2006.00499.x
22. Lai KC Lam SK Chu KM, et al. Lansoprazole for the prevention of recurrences of ulcer complications from long-term low-dose aspirin use. N Engl J Med 2002 346 : 2033 8.
23. Röhss K Lind T Wilder-Smith C. Esomeprazole 40 mg provides more effective intragastric acid control than lansoprazole 30 mg, omeprazole 20 mg, pantoprazole 40 mg and rabeprazole 20 mg in patients with gastro-oesophageal reflux symptoms. Eur J Clin Pharmacol 2004 60 : 531 9.
24. Griffin MR Piper JM Daugherty JR Snowden M Ray WA. Nonsteroidal anti-inflammatory drug use and increased risk for peptic ulcer disease in elderly patients. Ann Intern Med 1991 114 : 257 63.
25. Laine L Bombardier C Hawkey CJ, et al. Stratifying the risk of NSAID-related upper gastrointestinal clinical events: results of a double-blind outcomes study in patients with rheumatoid arthritis. Gastroenterology 2002 123 : 1006 12.